Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Appili Therapeutics Inc (TSX:APLI)

0.0275 -0.0025 (-8.33%)
Streaming Delayed Price Updated: 1:50 PM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Appili Therapeutics Inc

< Previous 1 2 3 Next >
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) to Host Appili CEO in April 4 Update Focused on Infectious Disease Innovation
Via Investor Brand Network
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Highlights CaSe Platform Acquisition in Weekly Update Focused on Early Cancer Detection
Via Investor Brand Network
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Pearsanta Acquires Patents for DNA Damage Detection in Cancer Prevention
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Provides Update on Appili Therapeutics Acquisition and Federal Funding Applications
Via Investor Brand Network
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Provides Corporate Update, Announces Weekly Investor Series
Via Investor Brand Network
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Advances ADI-100 Autoimmune Therapy Toward Clinical Trials
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Subsidiary Pearsanta Engages Lead Underwriter for Planned IPO
Via Investor Brand Network
Topics Initial Public Offering
Exposures Securities Market
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) to Host Fireside Chat on Feb. 21 to Discuss Key Corporate Developments
Via Investor Brand Network
Topics Initial Public Offering
Exposures Securities Market
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Explores IPO for Pearsanta to Advance Early Cancer Detection
Via Investor Brand Network
Topics Initial Public Offering
Exposures Securities Market
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Subsidiary Advances ADI-100 Gene Therapy Toward Human Trials
Via Investor Brand Network
Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials
From Aditxt, Inc.
Via Business Wire
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Updates Shareholders on Equity Issuance and Shift to Debt Financing Strategy
Via Investor Brand Network
Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares
From Aditxt, Inc.
Via Business Wire
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Acquisition of Appili Therapeutics Moves Forward with Overwhelming Shareholder Approval
Via Investor Brand Network
Aditxt’s Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders
From Aditxt, Inc.
Via Business Wire
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Gains Support for Evofem Merger as Voting Agreements Secure Favorable Votes
Via Investor Brand Network
Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem
From Aditxt, Inc.
Via Business Wire
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) to Hold CEO-Led Update and Q&A Session Covering Company Developments
Via Investor Brand Network
Aditxt’s Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission
From Aditxt, Inc.
Via Business Wire
Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time
From Aditxt, Inc.
Via Business Wire
TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX) Strengthens Leadership with Appointment of Governance Expert Sylvia Hermina to Board
Via Investor Brand Network
Sylvia Hermina Joins Aditxt’s Board of Directors, Elevating Leadership with Broader Perspectives
From Aditxt, Inc.
Via Business Wire
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Moves Closer to Evofem Acquisition with Final Investment Milestone
Via Investor Brand Network
Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem
From Aditxt, Inc.
Via Business Wire
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Hosts Virtual Fireside Chat to Discuss Evofem Acquisition and Future Strategic Plans
Via Investor Brand Network
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Announces Acquisition Target Plans Special Meeting of Shareholders to Obtain Transaction Approval
Via Investor Brand Network
Aditxt’s Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili’s Shareholder Approval
From Aditxt, Inc.
Via Business Wire
InvestorNewsBreaks – Aditxt (NASDAQ: ADTX), Evofem Announce Completion of Third Parent Equity Investment Under Amended Merger Agreement
Via Investor Brand Network
InvestorNewsBreaks – Gaxos.ai Inc. (NASDAQ: GXAI) Announces Participation at the Upcoming Game Industry Conference
Via Investor Brand Network
InvestorNewsBreaks – Aditxt (NASDAQ: ADTX) Releases Shareholder Update, Plans for Remainder of 2024
Via Investor Brand Network
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.